AWKN — Awakn Life Sciences Cashflow Statement
0.000.00%
- CA$4.85m
- CA$4.72m
- CA$0.09m
Annual cashflow statement for Awakn Life Sciences, fiscal year end - January 31st, CAD millions except per share, conversion factor applied.
2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | -1.11 | -16.5 | -9.65 | -3.67 |
Depreciation | ||||
Non-Cash Items | 0.488 | 7.17 | 1.17 | 0.093 |
Discontinued Operations | ||||
Unusual Items | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | 0.132 | 0.538 | 0.51 | 1.18 |
Change in Accounts Receivable | ||||
Change in Prepaid Expenses | ||||
Change in Payable / Accrued Expenses | ||||
Change in Other Liabilities | ||||
Cash from Operating Activities | -0.473 | -8.59 | -7.36 | -2.38 |
Capital Expenditures | -0.201 | -1.71 | -0.095 | — |
Purchase of Fixed Assets | ||||
Purchase / Acquisition of Intangibles | ||||
Other Investing Cash Flow Items | -0.015 | 0.022 | 0 | -0.02 |
Acquisition of Business | ||||
Sale of Business | ||||
Other Investing Cash Flow | ||||
Cash from Investing Activities | -0.216 | -1.69 | -0.095 | -0.02 |
Financing Cash Flow Items | — | — | — | -0.2 |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 1.06 | 11.5 | 6.4 | 2.46 |
Foreign Exchange Effects | ||||
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | 0.366 | 1.26 | -1.07 | 0.041 |